Full Text View
Tabular View
No Study Results Posted
Related Studies
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
This study is currently recruiting participants.
Verified May 2012 by National Institutes of Health Clinical Center (CC)
Study NCT00326495   Information provided by National Institutes of Health Clinical Center (CC)

First Received on May 16, 2006.   Last Updated on May 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Colorectal Cancer
EGFR-Expressing Metastatic CRC
Additional conditions recognized in this trial
Colorectal Neoplasms
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Sorafenib (Bay 43-9006)
cetuximab
proteomic profiling
immunoenzyme technique
laboratory biomarker analysis
pharmacological study
biopsy
Additional drug interventions recognized in this trial
Sorafenib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services